Literature DB >> 25477610

Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung Cancer.

Benjamin G Mancheril1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 25477610      PMCID： PMC4252182          DOI： 10.1310/hpj4909-804

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  14 in total

1.  Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.

Authors:  Jon D Herrington; Hai T Tran; Mark W Riggs
Journal:  Cancer Chemother Pharmacol       Date:  2005-08-25       Impact factor: 3.333

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

Authors:  Olga Geling; Hans-Georg Eichler
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

4.  A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.

Authors:  Mark A Socinski; Georgiy M Manikhas; Daniil L Stroyakovsky; Anatoly N Makhson; Sergey V Cheporov; Sergei V Orlov; Petr K Yablonsky; Paul Bhar; Jose Iglesias
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

5.  Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.

Authors:  Miyako Satouchi; Isamu Okamoto; Hiroshi Sakai; Nobuyuki Yamamoto; Yukito Ichinose; Hironobu Ohmatsu; Naoyuki Nogami; Koji Takeda; Tetsuya Mitsudomi; Kazuo Kasahara; Shunichi Negoro
Journal:  Lung Cancer       Date:  2013-03-30       Impact factor: 5.705

6.  A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.

Authors:  Paul K Paik; Leonard P James; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Camelia S Sima; Robert T Heelan; Mark G Kris; Erin Moore; Naiyer A Rizvi
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-03       Impact factor: 3.333

7.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

8.  Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.

Authors:  Y W Cheung; J C Cradock; B R Vishnuvajjala; K P Flora
Journal:  Am J Hosp Pharm       Date:  1987-01

9.  Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

Authors:  M A Socinski; C J Langer; I Okamoto; J K Hon; V Hirsh; S R Dakhil; R D Page; J Orsini; H Zhang; M F Renschler
Journal:  Ann Oncol       Date:  2012-11-02       Impact factor: 32.976

10.  Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors:  Dieter Kaag
Journal:  Lung Cancer       Date:  2012-11-04       Impact factor: 5.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.